Bristol-Myers Squibb Company (NYSE:BMY) had its price target lifted by Citigroup Inc. to $72.00 in a note issued to investors on Wednesday, October 18th. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup Inc.’s price target would indicate a potential upside of 18.13% from the stock’s previous close.
Several other research analysts have also recently commented on BMY. William Blair reiterated an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Monday, June 26th. BidaskClub raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Cowen and Company set a $65.00 price objective on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, July 10th. Jefferies Group LLC reaffirmed a “buy” rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a report on Wednesday, July 12th. Finally, Vetr raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $62.23 target price for the company in a report on Wednesday, July 12th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and ten have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $64.53.
Shares of Bristol-Myers Squibb (NYSE BMY) opened at 60.95 on Wednesday. The stock has a market capitalization of $99.95 billion, a price-to-earnings ratio of 22.26 and a beta of 1.19. Bristol-Myers Squibb has a one year low of $46.01 and a one year high of $66.10. The firm’s 50-day moving average is $63.60 and its 200-day moving average is $57.54.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.77 EPS. Equities research analysts forecast that Bristol-Myers Squibb will post $2.99 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Bristol-Myers Squibb Company (NYSE:BMY) Given New $72.00 Price Target at Citigroup Inc.” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2017/10/27/bristol-myers-squibb-company-bmy-pt-raised-to-72-00.html.
In other news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the sale, the senior vice president now owns 46,297 shares of the company’s stock, valued at $2,777,820. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Theodore R. Samuels II purchased 6,000 shares of the stock in a transaction that occurred on Wednesday, August 2nd. The stock was bought at an average cost of $55.94 per share, with a total value of $335,640.00. Following the acquisition, the director now owns 18,000 shares of the company’s stock, valued at $1,006,920. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Waldron LP bought a new stake in Bristol-Myers Squibb in the 1st quarter valued at $475,000. Leavell Investment Management Inc. lifted its position in Bristol-Myers Squibb by 3.1% in the 1st quarter. Leavell Investment Management Inc. now owns 21,471 shares of the biopharmaceutical company’s stock valued at $1,168,000 after acquiring an additional 650 shares in the last quarter. Breton Hill Capital Ltd. bought a new stake in Bristol-Myers Squibb in the 1st quarter valued at $1,335,000. Oakworth Capital Inc. lifted its position in Bristol-Myers Squibb by 3.7% in the 1st quarter. Oakworth Capital Inc. now owns 10,830 shares of the biopharmaceutical company’s stock valued at $589,000 after acquiring an additional 385 shares in the last quarter. Finally, Dillon & Associates Inc. lifted its position in Bristol-Myers Squibb by 7.0% in the 1st quarter. Dillon & Associates Inc. now owns 4,225 shares of the biopharmaceutical company’s stock valued at $228,000 after acquiring an additional 275 shares in the last quarter. 68.90% of the stock is currently owned by institutional investors.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.